Biogen Inc vs SAP SE — how do they compare? Biogen Inc trades at $205.52 (market cap $30.13B), while SAP SE trades at $202.75 (market cap $240.81B). The key difference: SAP SE is far larger — about 8× Biogen Inc's market cap, and SAP SE pays a 1.4% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SAP | |
|---|---|---|
Market Cap | $30.13B | $240.81B |
Sector | Health | Technology |
52-Week High | $216.63 | $280.46 |
52-Week Low | $128.93 | $146.38 |
Enterprise Value | $37.20B | $239.52B |
Dividend Yield | — | 1.4% |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
SAP trades at $208.55, up 1.16% today, near its consensus price target of $209.67. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but revenue grew, driven by cloud demand. The company maintains robust profitability with a net income margin of 20.41% and solid cash flow from operations of $9.16B in 2025.
Outlook is mixed: AI and cloud growth offer upside, but profit guidance cuts and execution risks pose challenges. Analysts are generally bullish (53.49% buy ratings), yet investors should weigh high valuation multiples against competitive pressures in enterprise software. Near-term resistance lies at $211.
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →